NASDAQ
16.63USD
-0.15 (-0.89%)
We have scored 3 news catalysts on Apnimed, Inc. (APMD) over the past 12 months. The biggest single-day move next to one of them came Sep 10, 2026, when APMD closed −4.6%: “Apnimed: What We Know Heading Into The Feb PDUFA”. Coverage across the window leans positive (average ticker sentiment +0.97). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
692.3M
P/E
—
EPS
—
Beta
7.95
52W range
13.88-35.29
Day range
16.16–16.99
Open
16.81
Prev close
16.78
Volume
278.6K
Avg volume
487.8K
Dividend
0.00
IPO
2026-07-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Apnimed, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for APMD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
